Ultrasound sales to post healthy growth
Innovations in radiology and cardiology will boost the U.S. ultrasound market over the next three years, according to a study conducted by Datamonitor, a market analysis firm specializing in the medical equipment and healthcare industries. Ultrasound
Innovations in radiology and cardiology will boost the U.S. ultrasound market over the next three years, according to a study conducted by Datamonitor, a market analysis firm specializing in the medical equipment and healthcare industries. Ultrasound should see a compound annual growth rate of approximately 7% over the next five years and will climb from its current $943 million market to $1.2 billion by 2003, Datamonitors Trends and Dynamics in U.S. Ultrasound 1999 report claims. Ultrasounds radiology segment represents about 40% of the overall ultrasound market, while cardiology represents about 35%, according to the report.
Acuson, Philips/ATL Ultrasound, and Hewlett-Packard are the top three companies in ultrasound, with GE Medical Systems and Toshiba America Medical Systems ranked next, according to the New York-based firm.
Although ultrasound sales have traditionally been driven by mid-range systems, this segment is now the smallest in both revenue and volume, since its technology has begun trickling down to low-end systems. Datamonitor predicts that although all segments of the ultrasound market will see growth, sales of high-end radiology and cardiology units will particularly increase, as their technology becomes more capable of competing with such other imaging modalities as MRI and CT.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
